Lineage Cell Therapeutics (LCTX) Net Margin (2016 - 2025)
Historic Net Margin for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to 92.91%.
- Lineage Cell Therapeutics' Net Margin fell 135000.0% to 92.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 296.07%, marking a year-over-year decrease of 661600.0%. This contributed to the annual value of 195.62% for FY2024, which is 445000.0% up from last year.
- Latest data reveals that Lineage Cell Therapeutics reported Net Margin of 92.91% as of Q3 2025, which was down 135000.0% from 698.95% recorded in Q2 2025.
- In the past 5 years, Lineage Cell Therapeutics' Net Margin ranged from a high of 56.02% in Q4 2021 and a low of 969.73% during Q2 2021
- Its 5-year average for Net Margin is 313.58%, with a median of 225.77% in 2023.
- As far as peak fluctuations go, Lineage Cell Therapeutics' Net Margin skyrocketed by 12693600bps in 2021, and later tumbled by -3704800bps in 2023.
- Over the past 5 years, Lineage Cell Therapeutics' Net Margin (Quarter) stood at 56.02% in 2021, then plummeted by -493bps to 332.22% in 2022, then surged by 32bps to 225.77% in 2023, then surged by 50bps to 113.32% in 2024, then grew by 18bps to 92.91% in 2025.
- Its Net Margin was 92.91% in Q3 2025, compared to 698.95% in Q2 2025 and 401.26% in Q1 2025.